Earlier Answers, Earlier Action: Public Attitudes Toward Alzheimer's Disease Risk, Diagnosis, and Care
Research conducted by Ipsos in collaboration with and funded by Eli Lilly explores current beliefs, preferences, and perceptions surrounding Alzheimer's disease.
The study results are available for download here
About the Study
These are some of the findings of Ipsos research conducted in collaboration with and funded by Eli Lilly and Company.
Ipsos fielded an online, 20-minute, self-administered, cross-sectional survey from April 9th – May 26th, 2026. The survey was fielded in the United States, Germany, Brazil, China, and Japan, with all surveys administered in local language. All respondents were recruited from opt-in online research panels. The final sample size of 4,625 respondents included 2,500 general population respondents, 500 patients with memory and thinking issues, 495 patients without memory and thinking issues, 478 care partners, and 902 HCPs. Findings presented in this paper reflect the opinion of these respondents only.
This multinational survey was conducted to better understand current beliefs, preferences, and perceptions surrounding Alzheimer's disease. Ultimately, the survey findings reveal that many people want answers sooner about their AD risk and status. However, limited awareness of available diagnostic options and challenges navigating the path to diagnosis may continue to delay action. Understanding this gap between intent and action is critical to improving the AD care journey.
About Ipsos
Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 20,000 people.
Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. We serve more than 5000 clients across the world with 75 business solutions.
Founded in France in 1975, Ipsos is listed on the Euronext Paris since July 1st, 1999. The company is part of the SBF 120 and the Mid-60 index and is eligible for the Deferred Settlement Service (SRD). ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com
35 rue du Val de Marne
75 628 Paris, Cedex 13 France
Tel. +33 1 41 98 90 00